Literature DB >> 582775

N-Nitroso compound contaminants in prescription and nonprescription drugs.

I S Krull, U Goff, A Silvergleid, D H Fine.   

Abstract

73 pharmaceutical products, consisteing of both prescription and over-the-counter drugs have been analyzed by gas chromatography-thermal energy analysis (GC-TEA) and high-pressure liquid chromatography-thermal energy analysis (HPLC-TEA) for the presence of N-nitroso compound contaminants. The methods used were designed to detect both volatile and non-volatile N-nitroso compounds at levels down to 1 ng/g (1 ppb). Results presented here indicate that N-nitroso compound impurities are absent from the majority of the products tested. However, for 3 of the drugs, our analysis suggests the possible presence of N-nitroso compounds at levels up to 81 ng/g (81 ppb). The identity of the suspect N-nitroso compounds have not yet been established. In the case of the over-the-counter drugs, two of these have been shown to contain TEA responsive materials (126 ppb, 406 ppb), that may appear to be O-nitroso compounds rather than N-nitroso.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582775

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Modulation of N-Methyl-N-nitrosourea Mutagenesis in Mouse Embryo Fibroblasts Derived from the gpt Delta Mouse by an Inhibitor of the O6-Methylguanine Methyltransferase, MGMT.

Authors:  Pennapa Thongararm; Bogdan I Fedeles; Sakunchai Khumsubdee; Amanda L Armijo; Lina Kim; Apinya Thiantanawat; Jeerawan Promvijit; Panida Navasumrit; Mathuros Ruchirawat; Robert G Croy; John M Essigmann
Journal:  Chem Res Toxicol       Date:  2019-12-24       Impact factor: 3.739

Review 2.  International Regulatory Collaboration on the Analysis of Nitrosamines in Metformin-Containing Medicines.

Authors:  David A Keire; Robert Bream; Uwe Wollein; Jeannette Schmaler-Ripcke; Annette Burchardt; Massimiliano Conti; Adam Zmysłowski; Peter Keizers; Justin Morin; Jalene Poh; Mark George; Michael Wierer
Journal:  AAPS J       Date:  2022-04-21       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.